232 related articles for article (PubMed ID: 15312855)
1. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
2. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity.
Briguori C; Colombo A; Violante A; Balestrieri P; Manganelli F; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Focaccio A; Librera M; Bonizzoni E; Ricciardelli B
Eur Heart J; 2004 Feb; 25(3):206-11. PubMed ID: 14972420
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
[TBL] [Abstract][Full Text] [Related]
6. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
7. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
8. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
[TBL] [Abstract][Full Text] [Related]
9. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
[TBL] [Abstract][Full Text] [Related]
11. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
12. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
14. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
Hafiz AM; Jan MF; Mori N; Shaikh F; Wallach J; Bajwa T; Allaqaband S
Catheter Cardiovasc Interv; 2012 May; 79(6):929-37. PubMed ID: 21542114
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
16. Acetylcysteine and contrast agent-associated nephrotoxicity.
Briguori C; Manganelli F; Scarpato P; Elia PP; Golia B; Riviezzo G; Lepore S; Librera M; Villari B; Colombo A; Ricciardelli B
J Am Coll Cardiol; 2002 Jul; 40(2):298-303. PubMed ID: 12106935
[TBL] [Abstract][Full Text] [Related]
17. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
[TBL] [Abstract][Full Text] [Related]
18. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
19. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
20. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]